Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key ...

Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...

A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...

FutureG Office is investing in cutting-edge, next-gen techIt has handed $28m in funding to Cohere Technologies for the ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

Rao Bahadur has opened to encouraging reactions on social media, with many viewers applauding Satya Dev's performance and the film's unique psychological drama. Here's what audiences are saying.

In adolescents, the most common adverse events (occurring in =5% of ML-004-treated adolescents and at least twice the rate of placebo) were headache (13.7% vs. 3.9%), somnolence (11.8% vs. 0%), nausea ...